Eli Lilly CEO says Medicare coverage of obesity drugs could ‘change the game’ for upcoming pill launch
Eli Lilly CEO Dave Ricks on Friday said upcoming Medicare coverage of obesity drugs could be a major catalyst for ...
Tag: Novo Nordisk A/S
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026.George Frey | Bloomberg ...
This pharma stock just got whacked — there’s still a major catalyst ahead
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time ...
Novo Nordisk shares rise 8% after Wegovy obesity pill has ‘solid’ launch
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026.George Frey | Bloomberg ...
Behind Anthropic’s stunning growth is a sibling team that may hold the key to generative AI
SAN FRANCISCO — Daniela Amodei has an energy that's hard to place — warm, unhurried, immediately present. She swept into ...
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, ...
Nine of the largest pharma companies ink deals with Trump to lower drug prices
U.S. President Donald Trump speaks during an event in the Roosevelt Room of the White House December 19, 2025 in ...
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
Eli Lilly on Monday said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug ...
Millions more Americans could access obesity drugs after Trump’s deals with Eli Lilly, Novo Nordisk
US President Donald Trump makes an announcement in the Oval Office of the White House in Washington, DC on Nov. ...
Week in review: The Nasdaq’s worst week since April, three trades, and earnings
It was a terrible start to November on Wall Street. The tech-heavy Nasdaq sank just over 3% in its worst ...
